Gilead pays $43.5M for early-phase IL-12 prospect from Xilio as biotech reduces head count

Gilead pays $43.5M for early-phase IL-12 prospect from Xilio as biotech reduces head count
ntaylor


Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks